Abstract
Background: The prevalence of hepatotoxicity after longterm oral amiodarone therapy in Chinese patients with or without elevated liver enzymes at baseline is unknown.
Hypothesis: Amiodarone may still be safely prescribed for Chinese patients who have baseline liver dysfunction.
Methods: This is a retrospective cross‐sectional study. Significant liver dysfunction (SLD) was defined as alanine aminotransferase (ALT) > 2 times upper limit of normal range.
Results: Baseline liver function was checked in 628 of the 720 Chinese patients identified. The mean duration of amiodarone use was 615.9 ± 703.1 days. Ninety patients (14.3%) had elevated baseline ALT. The prevalence of SLD was 3.7% (confidence interval [CI] 2.1–5.3%) and 4.4% (CI 0.2–8.6%) in patients with normal (n = 53 8) and elevated (n = 90) baseline ALT, respectively (p = 0.765). Therapy was continued in 42 patients with elevated baseline ALT until final follow‐up. Eight of these (19.0%) had elevated ALT upon final follow‐up, but the derangement was mild (mean ALT 134.8 ± 145.9 IU/l, median 76 IU/l). During follow up, 24 patients developed SLD and half of these subsequently withdrew from therapy. The ALT levels at final follow‐up had improved overtime in both groups, but the mean difference was not significant (255.1 ± 706.4 vs. 131.0 ±207.5 IU/l, p = 0.312).
Conclusion: The prevalence of SLD in Chinese patients taking oral amiodarone with or without elevated baseline ALT was similar (4.4 vs. 3.7%). It seems that amiodarone may be safely prescribed in patients with elevated baseline ALT.
Keywords: amiodarone, Hepatotoxicity, Chinese
Full Text
The Full Text of this article is available as a PDF (39.3 KB).
References
- 1. Connolly SJ: Evidence‐based analysis of amiodarone efficacy and safety. Circulation 1999; 100: 2025–2034 [DOI] [PubMed] [Google Scholar]
- 2. Rigas B, Rosenfeld LE, Barwick KW, Enriquez R, Helzberg J, Batsford WP, Josephson ME, Riely CA: Amiodarone hepatotoxicity: A clinicopathologic study of five patients. Ann Intern Med 1986; 104: 348–351 [DOI] [PubMed] [Google Scholar]
- 3. Gehenot M, Horsmans Y, Rahier J, Geubel AP: Subfulminant hepatitis requiring liver transplantation after benzarone administration. J Hepatol 1994; 20: 842–842 [DOI] [PubMed] [Google Scholar]
- 4. Morelli S, Guido V, De Marzio P, Aguglia F, Balsano F: Early hepatitis during intravenous amiodarone administration. Cardiology 1991; 78: 291–294 [DOI] [PubMed] [Google Scholar]
- 5. Lewis JH, Ranard RC, Caruso A, Jackson LK, Mullick F, Ishak KG, Seeff LB, Zimmerman HJ: Amiodarone hepatotoxicity: Prevalence and clinicopathologic correlations among 104 patients. Hepatology 1989; 9: 679–685 [DOI] [PubMed] [Google Scholar]
- 6. Morse RM, Valenzuela GA, Greenwald TP, Eulie PJ, Wesley RC, McCallum RW: Amiodarone‐induced liver toxicity. Ann Intern Med 1988; 109: 838–840 [DOI] [PubMed] [Google Scholar]
- 7. Lee WM: Drug‐induced hepatotoxicity. N Engl J Med 1995; 333: 1118–1125 [DOI] [PubMed] [Google Scholar]
- 8. Amiodarone Trials Meta‐Analysis Investigators : Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta‐analysis of individual data from 6,500 patients in randomized trials. Lancet 1997; 350: 1417–1424 [PubMed] [Google Scholar]
- 9. Latorre G, Lucas I, Herrero JI, Sangro B, Quiroga J, Sola JJ, Diaz L, Prieto J: Severe hepatotoxicity caused by amiodarone: Description of a case. Revista de Medicina de la Universidad de Navarra 1999; 43 (2): 86–91 [PubMed] [Google Scholar]
- 10. Chang CC, Petrelli M, Tomashefski JF Jr, McCullough AJ: Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug: A case report and review of the literature. Arch Pathol Labor Med 1999; 123 (3): 251–256 [DOI] [PubMed] [Google Scholar]
- 11. Paniagua CJ, Arcusa GR, Goma MF, Pons MS, Soler Masana JM: Acute hepatitis caused by intravenous amiodarone. Rev Espan Cardiol 1996; 49 (5): 384–385 [PubMed] [Google Scholar]
- 12. Tagliamonte E, Cice G, Ducceschi V, Mayer MS, Iacono A: Acute hepatitis following amiodarone administration. Minerva Cardioangiolog 1997; 45 (9): 451–456 [PubMed] [Google Scholar]
- 13. Richer M, Robert S: Fatal hepatotoxicity following oral administration of amiodarone. Ann Pharmacother 1995; 29 (6): 582–586 [DOI] [PubMed] [Google Scholar]
- 14. Rhodes A, Eastwood JB, Smith SA: Early acute hepatitis with parenteral amiodarone: Atoxic effect of the vehicle? Gut 1993; 34 (4): 565–566 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Jeyamalar R, Pathmanathan R, Wong D, Kannan P: Hepatotoxicity of amiodarone. Ann Acad Med, Singapore 1992; 21 (6): 838–840 [PubMed] [Google Scholar]
- 16. Benbassat C, Shahar A: Acute fulminant hepatic failure after short‐term amiodarone. Harefuah 1991; 121 (10): 378–380 [PubMed] [Google Scholar]
- 17. Kalantzis N, Gabriel P, Mouzas J, Tiniakos D, Tsigas D, Tiniakos G: Acute amiodarone‐induced hepatitis. Hepato‐Gastroenterol 1991; 38 (1): 71–74 [PubMed] [Google Scholar]
- 18. Roche JF, Netter P, Gay G: Amiodarone‐induced hepatitis: Biological, histological diagnosis, development and role of associated factors. Review of the literature. Report of 2 cases. Rev Med Int 1989; 10 (6): 497–501 [DOI] [PubMed] [Google Scholar]
- 19. Gilinsky NH, Briscoe GW, Kuo CS: Fatal amiodarone hepatoxicity. Am J Gastroenterol 1988; 83 (2): 161–163 [PubMed] [Google Scholar]
- 20. Vorperian VR, Havighurst TC, Miller S, January CT: Adverse effects of low dose amiodarone: A meta‐analysis. J Am Coll Cardiol 1997; 30 (3): 791–798 [DOI] [PubMed] [Google Scholar]